Effect of Remote Counseling on Screening Uptake in the First-Degree Relatives of Colorectal Cancer Patients: A Systematic Review and Meta-analysis.

Cancer NursMar 10, 2025 (epub)

Bei Dong, Yongfeng Chen, Dongting Zhang et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis assessed remote counseling to promote colorectal cancer screening among first-degree relatives of people with colorectal cancer. It included five randomized controlled trials involving 2601 relatives. Remote counseling was associated with higher screening uptake than comparison approaches (relative risk, 1.65; 95% confidence interval, 1.46-1.86; P < .01). Mailing tailored printed materials also showed a beneficial effect. Evidence was limited on whether remote counseling improves relatives’ knowledge or health beliefs about colorectal cancer and screening.

Key findings

  • Across five studies and 2601 relatives, remote counseling increased screening uptake (relative risk, 1.65; 95% confidence interval, 1.46-1.86; P < .01).
  • Mailing tailored printed materials was beneficial for screening uptake (relative risk, 1.57; 95% confidence interval, 1.22-2.03; P < .01).
  • Evidence was limited regarding effects on knowledge and health beliefs about colorectal cancer and screening.

Why it matters

First-degree relatives of people with colorectal cancer are an important group for screening outreach. The pooled findings suggest that remote counseling can help increase screening uptake, including through tailored printed materials. However, the review provides limited evidence about changes in knowledge or health beliefs, so the mechanisms and optimal form of counseling remain uncertain.

What to keep in mind

Only five trials were included, and the review reports limited evidence on knowledge and health beliefs. The authors call for more rigorous, theory-driven randomized trials to identify an optimal intervention.

Source

Published in Cancer Nurs. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.